Path: /organizations/jpnd
Type: Intergovernmental Research Initiative / Funding Mechanism
Location: Brussels, Belgium (coordinated across 30+ countries)
Founded: 2009 (EU commission; first calls 2011)
Website: neurodegenerationresearch.eu
Participating Countries: 30+ EU member states and associated countries
The Joint Programme on Neurodegenerative Disease Research (JPND) is the largest European research initiative focused on neurodegenerative diseases, established in 2009 by the European Commission and national research funding agencies across 30+ countries. JPND coordinates national research funding to address the growing challenge of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, Progressive Supranuclear Palsy, and related disorders.
Unlike traditional funding mechanisms, JPND operates as a "meta-funding" body — coordinating calls for transnational research proposals where multiple national agencies co-fund the same project. This approach avoids duplication and maximizes impact by enabling large-scale, cross-border collaborations that no single national program could support alone.
¶ Mission and Objectives
JPND's mission is to coordinate national research efforts to:
- Accelerate understanding of neurodegenerative disease causes and mechanisms
- Improve early diagnosis through harmonized biomarker programs
- Develop effective treatments through transnational clinical collaboration
- Reduce duplication by coordinating national funding priorities
- Enable data sharing across European cohorts and biobanks
JPND's current strategy emphasizes:
- Harmonized data standards: Cross-national interoperability of patient data
- Cohort linkage: Connecting existing national cohorts for pan-European analyses
- Biomarker standardization: Validated fluid and imaging biomarkers across sites
- Patient involvement: Embedding patient perspectives in research design
- Industry engagement: Facilitating pharma/biotech participation in public-private projects
JPND's core mechanism is issuing joint transnational calls where:
- Multiple countries participate in the same funding call
- Research consortia include partners from at least 3 participating countries
- Each national agency funds its own research team
- Consortia share data, methodologies, and biological samples
- Typical JPND calls fund 5-15 consortia
- Total budget per call: €20-50 million
- Individual project funding: €1-5 million over 3-4 years
- Over 1 billion EUR invested since 2011
Recent JPND calls have addressed:
- Harmonized assessment of prodromal Alzheimer's (2023)
- Sex and gender differences in neurodegenerative disease (2022)
- Digital biomarkers for early detection (2021)
- Links between peripheral and CNS mechanisms (2020)
- Large-scale analysis of existing cohorts (2019)
- Innovative treatment approaches (2018)
- Biomarkers for disease modification (2016)
¶ Cohorts and Biobanks
JPND has invested heavily in harmonizing existing European cohorts:
- European ADNI (E-ADNI): Harmonized Alzheimer's disease imaging data
- LIDINA: Longitudinal studies on inflammatory mechanisms
- PROXIMA: Biomarker cross-validation across sites
- BIOMARKAPD: Blood-based biomarker standardization for AD and PD
JPND has developed:
- Harmonized metadata standards for neurodegeneration cohorts
- Cross-national data access procedures enabling researchers to request data from multiple countries
- Common data model for cohort interoperability
- Ethical framework for transnational data sharing
JPND supports:
- Standard operating procedures for brain tissue and biofluid handling
- Virtual biobank connecting 30+ national biobanks
- Quality assurance programs for sample integrity
- Cross-border sample transfer protocols
JPND includes national funding agencies from 30+ countries:
| Country |
Funding Agency |
ND Research Focus |
| Germany |
DFG, BMBF |
AD, PD, ALS, FTD |
| France |
ANR, INSERM |
Tauopathies, ALS |
| UK |
MRC, NIHR |
AD, PD, MND |
| Italy |
MIUR |
Neuroinflammation |
| Spain |
ISCIII |
Aging and dementia |
| Sweden |
VR, FORMAS |
PD, protein aggregation |
| Netherlands |
ZonMw |
Biomarkers, clinical trials |
| Belgium |
FWO, FRS |
Neurodegeneration mechanisms |
| Austria |
FWF |
Basic science |
| Switzerland |
SNSF |
PD, AD, rare diseases |
| Denmark |
Danish Council |
Biomarkers |
| Norway |
RCN |
Population-based studies |
| Finland |
Academy |
Neuroinflammation |
| Ireland |
SFI, HRB |
Clinical research |
| Poland |
NCBR, NCN |
Genetics |
| Czech Republic |
GA CR |
Basic mechanisms |
| Hungary |
NKFI |
Clinical cohorts |
JPND supports PSP-related research through:
- Tauopathy calls: Multiple JPND grants fund 4R-tauopathy studies
- Biomarker programs: Blood NfL and tau validated for PSP cohorts across Europe
- Cohort linkage: European PSP patients in harmonized datasets
- Clinical trial networks: Infrastructure for cross-national PSP trials
- Brain bank coordination: Standards for PSP tissue handling across the EU
Within JPND's broader neurodegeneration framework, areas particularly relevant to PSP include:
- 4R-tau isoform biology and selective vulnerability
- Fluid biomarkers for PSP diagnosis and progression monitoring
- Imaging endpoints for clinical trials (tau PET, MRI)
- Genetic risk factors for sporadic and familial PSP
- Natural history studies across European populations
- Trial readiness infrastructure for upcoming therapeutic trials
¶ Impact and Achievements
JPND-funded research has produced:
- Harmonized cohort data from 50+ European studies
- Standardized biomarker protocols adopted across 20+ countries
- Open data platform with 100,000+ participants
- Cross-border research collaborations impossible under single-country funding
- New methodological approaches validated across diverse populations
- PRODEMOS: Precision prevention in dementia using lifestyle and medical interventions
- EPAD: European Prevention for Alzheimer's Disease longitudinal cohort
- EPAPP: Alzheimer's Prevention clinical trials platform
- MIRAGE: Multi-arm trials for neuroprotection
JPND calls are announced annually, typically with:
- Application deadline: Autumn (September-October)
- Review period: 6-9 months
- Funding start: Following year
- Minimum 3 countries from JPND participating list
- Balanced participation across partner countries
- Clear data sharing plan
- Patient and public involvement strategy
Researchers should:
- Monitor JPND website for upcoming calls
- Identify potential international collaborators early
- Develop data sharing protocols before applying
- Engage patient groups in research design